Payment overview · 2025
General Payments
$484.58
12 reported records · 6 companies
Healthcare provider profile · identity verified
Manish S Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ELIZABETH, NJ · NPI 1053418459
Verified facts
What the public records show
CMS Open Payments records show Manish S Patel, MD received $484.58 in general payments during 2025 across 12 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $176.91 | 36.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $125.00 | 25.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $114.52 | 23.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.13 | 6.2% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.00 | 5.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.02 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $484.58 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $137.66 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $114.52 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $39.25 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 226 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
226 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 88 |
| Metformin Hcl | Metformin Hcl | 292 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 52 |
| Carvedilol | Carvedilol | 248 | 59 |
| Losartan Potassium | Losartan Potassium | 228 | 58 |
| Eliquis | Apixaban | 226 | 22 |
| Furosemide | Furosemide | 170 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 45 |
| Januvia | Sitagliptin Phosphate | 155 | 20 |
| Gabapentin | Gabapentin | 152 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 131 | 65 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 130 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 14 |
| Famotidine | Famotidine | 116 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 31 |
| Omeprazole | Omeprazole | 101 | 33 |
| Ibuprofen | Ibuprofen | 92 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 26 |
| Tramadol Hcl | Tramadol Hcl | 87 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 24 |
| Alprazolam | Alprazolam | 82 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 19 |
| Montelukast Sodium | Montelukast Sodium | 80 | 31 |
| Lisinopril | Lisinopril | 79 | 19 |
| Azithromycin | Azithromycin | 77 | 59 |
| Meclizine Hcl | Meclizine Hcl | 77 | 21 |
| Memantine Hcl | Memantine Hcl | 73 | suppressed |
| Ozempic | Semaglutide | 72 | 13 |
| Glipizide Er | Glipizide | 71 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | 15 |
| Sertraline Hcl | Sertraline Hcl | 71 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 13 |
| Nifedipine Er | Nifedipine | 69 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 31 |
| Levetiracetam | Levetiracetam | 67 | 11 |
| Valsartan | Valsartan | 67 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 32 |
| Enalapril Maleate | Enalapril Maleate | 59 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 16 |
| Potassium Chloride | Potassium Chloride | 58 | 12 |
| Sucralfate | Sucralfate | 57 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Glipizide | Glipizide | 54 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 53 | 13 |
| Methylprednisolone | Methylprednisolone | 51 | 35 |
| Simvastatin | Simvastatin | 51 | 15 |
| Metformin Hcl Er | Metformin Hcl | 49 | 16 |
| Pregabalin | Pregabalin | 49 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Levofloxacin | Levofloxacin | 46 | 36 |
| Ammonium Lactate | Ammonium Lactate | 45 | 21 |
| Ezetimibe | Ezetimibe | 45 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 44 | 14 |
| Celecoxib | Celecoxib | 44 | 14 |
| Alendronate Sodium | Alendronate Sodium | 43 | 11 |
| Brilinta | Ticagrelor | 42 | suppressed |
| Naproxen | Naproxen | 42 | 21 |
| Risperidone | Risperidone | 42 | suppressed |
| Latanoprost | Latanoprost | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 11 |
| Hydrocortisone | Hydrocortisone | 38 | 21 |
| Linzess | Linaclotide | 38 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lactulose | Lactulose | 35 | 13 |
| Meloxicam | Meloxicam | 35 | 16 |
| Nitroglycerin | Nitroglycerin | 35 | 12 |
| Clonidine | Clonidine | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Prednisone | Prednisone | 33 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 19 |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | 11 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 16 |
| Synjardy | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Colchicine | Colchicine | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | 11 |
| Ursodiol | Ursodiol | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Kristalose | Lactulose | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $484.58 · 12 records | E.R. Squibb & Sons, L.L.C. | CAMZYOS, ELIQUIS, FREESTYLE LIBRE 3, Ozempic, Rybelsus, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error